

Mark J Roschewski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7313702/publications.pdf>

Version: 2024-02-01

63
papers

3,634
citations

279701

23
h-index

138417

58
g-index

64
all docs

64
docs citations

64
times ranked

5659
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Tumor DNA in Lymphoma: Principles and Future Directions. Blood Cancer Discovery, 2022, 3, 5-15.	2.6	25
2	CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage. Leukemia and Lymphoma, 2022, 63, 911-917.	0.6	2
3	Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. Blood Advances, 2022, 6, 2667-2680.	2.5	17
4	CAR T-Cell Therapy for Large B-Cell Lymphoma – Who, When, and How?. New England Journal of Medicine, 2022, 386, 692-696.	13.9	42
5	Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. Leukemia and Lymphoma, 2022, 63, 1728-1732.	0.6	2
6	Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?. Journal of Clinical Oncology, 2022, , JCO2102593.	0.8	1
7	Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood, 2022, 139, 2306-2315.	0.6	62
8	Prophylaxis and Management of Secondary CNS Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	0
9	The balancing act in Burkitt lymphoma. Blood, 2021, 137, 289-291.	0.6	0
10	Sorting biologic subtypes of primary CNS lymphoma. Blood, 2021, 137, 1436-1437.	0.6	5
11	Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nature Biotechnology, 2021, 39, 1537-1547.	9.4	151
12	A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies. Leukemia and Lymphoma, 2021, 62, 2625-2636.	0.6	3
13	Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2021, 39, 2605-2616.	0.8	37
14	Next-Generation Sequencing-Based Monitoring of Circulating Tumor DNA Reveals Clonotypic Heterogeneity in Untreated PTCL. Blood Advances, 2021, 5, 4198-4210.	2.5	8
15	The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15th CML workshop on ctDNA. Hematological Oncology, 2020, 38, 34-37.	0.8	22
16	Expanding the Precision Medicine Toolkit With Circulating Tumor DNA. JCO Oncology Practice, 2020, 16, 569-570.	1.4	0
17	<p></p>Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies</p>. OncoTargets and Therapy, 2020, Volume 13, 8323-8335.	1.0	14
18	Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. Journal of Clinical Oncology, 2020, 38, 2519-2529.	0.8	93

#	ARTICLE	IF	CITATIONS
19	Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. <i>Science Immunology</i> , 2020, 5, .	5.6	304
20	Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma. <i>Blood</i> , 2020, 136, 12-13.	0.6	7
21	Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma. <i>Blood</i> , 2020, 136, 24-25.	0.6	7
22	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. <i>Cell</i> , 2019, 178, 699-713.e19.	13.5	138
23	Liquid biopsy in non-Hodgkin's lymphoma. <i>Hematological Oncology</i> , 2019, 37, 70-74.	0.8	15
24	One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 467-476.	1.8	6
25	Reply to J. Wang et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 755-757.	0.8	2
26	Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2845-2853.	0.8	313
27	Dose-Adjusted Teddi-R Induces Durable Complete Remissions in Relapsed and Refractory Primary CNS Lymphoma. <i>Blood</i> , 2018, 132, 4195-4195.	0.6	7
28	Acalabrutinib combined with PI3K γ inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7518-7518.	0.8	6
29	Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. <i>Cancer Cell</i> , 2017, 31, 833-843.e5.	7.7	383
30	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. <i>Blood Advances</i> , 2017, 1, 1911-1918.	2.5	37
31	Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. <i>Haematologica</i> , 2016, 101, e27-e29.	1.7	24
32	Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. <i>Blood</i> , 2016, 127, 3127-3132.	0.6	59
33	Precision monitoring takes the stage. <i>Blood</i> , 2016, 128, 149-150.	0.6	1
34	Pathogenic role of B-cell receptor signaling and canonical NF- κ B activation in mantle cell lymphoma. <i>Blood</i> , 2016, 128, 82-92.	0.6	141
35	Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas. <i>Current Treatment Options in Oncology</i> , 2016, 17, 47.	1.3	27
36	Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2015, 1, 746.	3.4	266

#	ARTICLE	IF	CITATIONS
37	Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method. <i>Leukemia and Lymphoma</i> , 2015, 56, 1416-1424.	0.6	23
38	Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. <i>Lancet Oncology</i> , The, 2015, 16, 541-549.	5.1	346
39	Increased Serum Free Light Chains Precede the Presentation of Immunoglobulin Light Chain Amyloidosis. <i>Journal of Clinical Oncology</i> , 2014, 32, 2699-2704.	0.8	51
40	Smoldering multiple myeloma: present position and potential promises. <i>European Journal of Haematology</i> , 2014, 92, 1-12.	1.1	5
41	Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials. <i>Haematologica</i> , 2014, 99, 1769-1771.	1.7	3
42	Intraocular (vitreoretinal) lymphoma with renal, pelvic, and central nervous system lesions. <i>Canadian Journal of Ophthalmology</i> , 2014, 49, e104-e106.	0.4	2
43	Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease. <i>Cytokine</i> , 2014, 69, 294-297.	1.4	15
44	Diffuse large B-cell lymphoma—treatment approaches in the molecular era. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 12-23.	12.5	333
45	A prospective study of mediastinal gray-zone lymphoma. <i>Blood</i> , 2014, 124, 1563-1569.	0.6	100
46	Non-Hodgkin Lymphoma. , 2014, , 2033-2059.e8.		1
47	Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age. <i>American Journal of Hematology</i> , 2013, 88, 89-92.	2.0	7
48	Evolving therapeutic paradigms for multiple myeloma: back to the future. <i>Leukemia and Lymphoma</i> , 2013, 54, 451-463.	0.6	15
49	CD5 ⁺ Diffuse Large B-Cell Lymphoma With Hemophagocytosis. <i>Journal of Clinical Oncology</i> , 2013, 31, e76-e79.	0.8	7
50	Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. <i>Leukemia and Lymphoma</i> , 2013, 54, 2215-2218.	0.6	86
51	Pursuing the curative blueprint for early myeloma. <i>Blood</i> , 2013, 122, 486-490.	0.6	17
52	Lymphomatoid Granulomatosis. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 469-474.	1.0	114
53	ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress. <i>Clinical Cancer Research</i> , 2012, 18, 1979-1991.	3.2	71
54	EBV-associated lymphomas in adults. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 75-89.	0.7	64

#	ARTICLE	IF	CITATIONS
55	Lymphomatoid Granulomatosis and Other Epstein-Barr Virus Associated Lymphoproliferative Processes. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 208-215.	1.2	66
56	Diffuse large B cell lymphoma: molecular targeted therapy. <i>International Journal of Hematology</i> , 2012, 96, 552-561.	0.7	19
57	Fatal transfusion-associated graft-versus-host disease with concomitant immune hemolysis in a group A combat trauma patient resuscitated with group O fresh whole blood. <i>Transfusion</i> , 2012, 52, 930-935.	0.8	30
58	Monoclonal Gammopathy of Undetermined Significance (MGUS) Precedes the Diagnosis of AL Amyloidosis by up to 14 Years. <i>Blood</i> , 2011, 118, 1827-1827.	0.6	5
59	FDG-PET SUV Correlates with Expression of Genes Reflecting Proliferation, Metabolism, and Oncogene Activity in Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2011, 118, 3670-3670.	0.6	3
60	Multiple myeloma with lacrimal gland amyloidosis and sarcoidosis. <i>American Journal of Hematology</i> , 2010, 85, 506-509.	2.0	13
61	FDG-PET as a Marker of tumor proliferation Compared to Gene-Expression Proliferation Scores, MIB1%, and LDH In Untreated Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2010, 116, 3093-3093.	0.6	2
62	A Phase II Trial of Pulse Dosing Lenalidomide: 3 Weeks On 3 Weeks off in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2009, 114, 3427-3427.	0.6	2
63	The PI3K Inhibitor ON 01910.Na Inhibits Critical Survival Pathways and Induces Apoptosis in CLL Cells through Induction of NOXA and BIM. <i>Blood</i> , 2009, 114, 412-412.	0.6	0